Docoh
Loading...

RGRX Regenerx Biopharmaceuticals

RegeneRx Biopharmaceuticals Inc. (“RegeneRx” or the “Company”) (OTCQB:RGRX) is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. We have formulated Tß4 into three distinct product candidates in clinical development:

Company profile

Ticker
RGRX
Exchange
CEO
J. J. Finkelstein
Employees
Incorporated
Location
Fiscal year end
Former names
ALPHA 1 BIOMEDICALS INC, ALPHA 1 BIOMEDICALS INC /DE/
SEC CIK
IRS number
521253406

RGRX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

2 Mar 21
21 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 427.9K 427.9K 427.9K 427.9K 427.9K 427.9K
Cash burn (monthly) (positive/no burn) 17.67K 122.63K 126.95K 69.5K 83.91K
Cash used (since last report) n/a 65.41K 453.97K 469.97K 257.31K 310.65K
Cash remaining n/a 362.49K -26.07K -42.07K 170.59K 117.25K
Runway (months of cash) n/a 20.5 -0.2 -0.3 2.5 1.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Oct 20 Essetifin SPA Common Stock Warrant Common Stock Other Aquire J No No 0.45 835,189 375.84K 835,189
15 Oct 20 Essetifin SPA Convertible Promissory Note Common Stock Buy Aquire P No No 400000 - [object Object] -
15 Oct 20 Bove Mauro Common Stock Warrant Common Stock Buy Aquire P No No 0.45 20,880 9.4K 20,880
15 Oct 20 Bove Mauro Convertible Promissory Note Common Stock Buy Aquire P No No 10000 - 10K -
15 Oct 20 Finkelstein J J Common Stock Warrant Common Stock Buy Aquire P No No 0.45 20,880 9.4K 20,880
15 Oct 20 Finkelstein J J Convertible Promissory Note Common Stock Buy Aquire P No No 10000 - 10K -
15 Oct 20 Goldstein Allan L Common Stock Warrant Common Stock Buy Aquire P No No 0.45 10,440 4.7K 10,440
15 Oct 20 Goldstein Allan L Convertible Promissory Note Common Stock Buy Aquire P No No 5000 - 5K -
13 Feb 20 Goldstein Allan L Common Stock Gift Dispose G No No 0 200,000 0 1,512,793

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

38.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 1
Opened positions 0 1 EXIT
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 22.85M 22.85M
Total shares 51.52M 51.52M
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Essetifin SPA 51.52M $22.85M 0.0%
Largest transactions
Shares Bought/sold Change
Essetifin SPA 51.52M 0 0.0%

Financial report summary

?
Competition
Kala Pharmaceuticals
Management Discussion
  • Revenues. For the year ended December 31, 2020, we recorded revenue in the amount of approximately $77,000 versus $77,000 recorded for the year ended December 31, 2019. The revenue reflects the amortization over 30 years of the payments we received under the original joint venture license agreement and the payment we received for the expansion of the territorial rights to include Canada in April 2016. The payments received under the 2017 RGN-137 license amendment were amortized for revenue over 23 years.
  • Expenses — Research and development. For the year ended December 31, 2020, our R&D expenditures decreased by $60,000, or 92%, to $5,000, from approximately $65,000 in 2019. The limited R&D expenditures reflects the shift of our internal R&D efforts as our partners assume full responsibility for clinical development. The decrease in 2020 results from the classification of stock option compensation expense in G&A to more accurately reflect the Company’s current operations versus 2019. We expect our R&D expenses will remain at low levels unless we decide to reinitiate internal R&D efforts for our unpartnered programs.
  • Expenses — General and administrative. For the year ended December 31, 2020, our G&A expenses increased by approximately $93,000, or 7%, to $1,366,000 from $1,274,000 in 2019. Increases are reflected in 2020 expenses for personnel and related (increase of $39,000) and stock option compensation expense (increase of $125,000) , These increases were partially offset by decreases in professional fees (decrease of $7,000), insurance (decrease of $13,000), sponsorship (decrease of $5,000), travel (decrease of $9,000), investor relations (decrease of $25,000), facility and related (decrease of $4,000), license fees (decrease of $2,000) and other (decrease of $6,000). We believe that our G&A expenses will remain at current levels as we wait for data from the upcoming clinical trials being conducted by our partners. If we enter into additional partnerships or other business transactions, including financings, we will incur additional legal and transaction related expenses.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Aid, analyst, binding, BLA, BPCI, bradykinin, breakdown, carbon, category, CBER, CDER, chance, chapter, check, Chi, chromosome, Circulation, conjunctiva, contraindicated, corticosteroid, COVID, dampen, delinquent, depth, died, dilation, dioxide, disbursement, durability, elevated, endpoint, etabonate, excessive, explanation, fibrin, filer, Fisher, Flexibility, fungal, hormone, hyaluronic, hypotension, impossible, incidence, Innovation, insulin, intraocular, IOP, jurisdiction, Kala, leakage, leaky, linked, loan, locked, loteprednol, mark, men, military, morbidity, mortality, mycobacterial, pancreatic, pandemic, Paycheck, pediatric, perforation, permeability, PNC, PPACA, PPP, preceding, prepayment, prevalence, ratio, repay, repeat, reproductive, revised, saliva, seasoned, shell, slightly, square, storm, stream, strongly, Supplementary, suspension, technical, timeline, topline, unclear, Undefeated, uptake, viral, vulnerable
Removed: afforded, andin, applied, assessing, Carlo, converted, counterparty, customized, embody, Estimating, hedge, host, hyperbaric, implementation, incremental, inflow, inin, inInternal, inNature, journalCirculation, journalNature, Monte, ninety, notably, notional, permitted, remeasured, sensitive, settlement, simulation, sinaf, theJournal, therapy, waived